Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.60
-0.4%
$11.11
$6.39
▼
$26.95
$895.83M1.571.02 million shs751,024 shs
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
$3.11
-2.8%
$4.48
$1.57
▼
$9.44
$319.03M1.311.79 million shs11.96 million shs
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
$7.13
-12.6%
$12.07
$6.84
▼
$32.80
$1.97B2.7914.81 million shs17.25 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-0.38%-6.61%+11.34%-28.52%+20.87%
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
-2.81%+41.36%0.00%-39.38%-22.44%
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
-12.62%-18.61%-32.35%-61.48%-50.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.60
-0.4%
$11.11
$6.39
▼
$26.95
$895.83M1.571.02 million shs751,024 shs
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
$3.11
-2.8%
$4.48
$1.57
▼
$9.44
$319.03M1.311.79 million shs11.96 million shs
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
$7.13
-12.6%
$12.07
$6.84
▼
$32.80
$1.97B2.7914.81 million shs17.25 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-0.38%-6.61%+11.34%-28.52%+20.87%
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
-2.81%+41.36%0.00%-39.38%-22.44%
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
-12.62%-18.61%-32.35%-61.48%-50.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.88
Moderate Buy$32.83209.75% Upside
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
2.71
Moderate Buy$11.00253.70% Upside
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
2.69
Moderate Buy$32.29352.82% Upside

Current Analyst Ratings Breakdown

Latest CRVS, NUAI, and USAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
DowngradeOutperform ➝ Market Perform
11/13/2026
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
Boost Price TargetBuy$7.00 ➝ $17.00
11/12/2026
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
Reiterated RatingSell (D-)
11/11/2026
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
Reiterated RatingBuy
11/11/2026
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
DowngradeHold ➝ Strong Sell
11/10/2026
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
Lower Price TargetOverweight$40.00 ➝ $30.00
11/5/2026
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
Initiated CoverageBuy$6.00
11/4/2026
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
Reiterated RatingSell (D-)
10/30/2026
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
Lower Price TargetBuy$13.00 ➝ $10.00
10/29/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Set Price Target$27.00
10/26/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Reiterated RatingSell (D-)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/A$0.13 per share83.78$2.47 per shareN/A
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
$880K414.51N/AN/A($0.05) per share-62.20
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
$1.64M1,063.94N/AN/A$3.34 per share2.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$15.28M-$0.71N/AN/AN/AN/A-34.98%-32.67%N/A
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
-$29.59M-$0.93N/AN/AN/A-5,349.49%-121.03%-64.52%N/A
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
-$297.56M-$0.81N/AN/AN/A-716.54%-12.81%-10.79%N/A

Latest CRVS, NUAI, and USAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
-$0.13-$0.15-$0.02-$0.15N/A$0.15 million
11/9/2026Q3 2026
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
-$0.19-$0.44-$0.25-$0.02$6.50 million$3.00 million
11/5/2026Q3 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1924-$0.22-$0.0276-$0.22N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
N/AN/AN/AN/AN/A
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
13.38
13.38
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
0.11
14.21
14.21
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
N/A
32.79
31.80

Institutional Ownership

CompanyInstitutional Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
21.90%
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
N/A

Insider Ownership

CompanyInsider Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
19.70%
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
1.60%
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3784.35 million67.74 millionOptionable
New Era Energy & Digital Inc stock logo
NUAI
New Era Energy & Digital
5117.29 million115.42 millionOptionable
USA Rare Earth Inc. stock logo
USAR
USA Rare Earth
132244.72 million222.45 millionOptionable

Recent News About These Companies

USA Rare Earth (USAR) Stock Looks Below Fair Value After A 44% Slide
Why USA Rare Earth Stock Dropped Again Today
William Blair Downgrades USA Rare Earth Inc (USAR) to Market Perform
Bronze bull and bear statues face off in an urban financial district at sunset.
MarketBeat Week in Review – 11/9 - 11/13 (USAR)
...
Can USA Rare Earth Stock Jump 10X?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$10.60 -0.04 (-0.38%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$10.70 +0.10 (+0.93%)
As of 11/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

New Era Energy & Digital stock logo

New Era Energy & Digital NASDAQ:NUAI

$3.11 -0.09 (-2.81%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$3.13 +0.02 (+0.64%)
As of 11/16/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

New Era Energy & Digital, Inc., operates as an exploration and production platform, engages in the exploration, development, and production of helium, oil and natural gas, and natural gas liquids in the United States. The company owns and operates a portfolio of approximately 137,000 acres in Southeast New Mexico. Its flagship Pecos Slope Field covering an area of 1893 square kilometers located 20 miles north of Roswell, New Mexico. It serves Tier 2 gas companies and balloon gas distributors. The company was formerly known as New Era Helium, Inc. and changed its name to New Era Energy & Digital, Inc. in August 2025. New Era Energy & Digital, Inc. is based in Midland, Texas.

USA Rare Earth stock logo

USA Rare Earth NASDAQ:USAR

$7.13 -1.03 (-12.62%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$7.15 +0.02 (+0.34%)
As of 11/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.